Results 211 to 220 of about 2,907,437 (262)

Double-Blind

Annals of Internal Medicine, 2022
K. Julian
openaire   +3 more sources

Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial.

American Journal of Psychiatry, 2021
OBJECTIVE Depression is the leading cause of disability worldwide, and half of patients with depression have treatment-resistant depression. Intermittent theta-burst stimulation (iTBS) is approved by the U.S.
E. Cole, A. Phillips, B. Bentzley, K. Stimpson, R. Nejad, Fahim Barmak, Clive Veerapal, Naushaba Khan, K. Cherian, Emily Felber, Randi Brown, Elizabeth Choi, S. King, Heather Pankow, J. Bishop, A. Azeez, John P Coetzee, Rachel Rapier, N. Odenwald, David Carreon, J. Hawkins, Maureen Chang, J. Keller, K. Raj, C. Debattista, Booil Jo, F. Espil, A. Schatzberg, K. Sudheimer, N. Williams   +29 more
semanticscholar   +1 more source

Gold salts in the treatment of rheumatoid arthritis. A double-blind study.

Annals of Internal Medicine, 2020
A 2-year double-blind study was made of gold salt treatment in 27 patients who had active rheumatoid arthritis for less than 5 years.
J. W. Sigler, G. Bluhm, H. Duncan, J. Sharp, D. C. Ensign, McCrum Wr   +5 more
semanticscholar   +1 more source

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.

Journal of Clinical Oncology, 2019
PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC).
R. Finn, B. Ryoo, P. Merle, M. Kudo, M. Bouattour, Ho Yeong Lim, V. Breder, J. Edeline, Y. Chao, S. Ogasawara, T. Yau, M. Garrido, S. Chan, J. Knox, B. Daniele, S. Ebbinghaus, E. Chen, A. Siegel, A. Zhu, A. Cheng   +19 more
semanticscholar   +1 more source

Is Your ‘Double-Blind’ Design Truly Double-Blind?

British Journal of Psychiatry, 1989
Before a drug trial, researchers reasonably plan that participants will remain ignorant of which drug each patient is taking, reflected in the use of allegedly identical preparations. However, only rarely is this plan subjected to systematic scrutiny after the event, and our point of view is that this is unsatisfactory.
Alison Oxtoby, Angela Jones, Michael Robinson   +2 more
openaire   +3 more sources

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Archives of General Psychiatry, 1988
The treatment of schizophrenic patients who fail to respond to adequate trials of neuroleptics is a major challenge. Clozapine, an atypical antipsychotic drug, has long been of scientific interest, but its clinical development has been delayed because of
J. Kane, G. Honigfeld, J. Singer, H. Meltzer   +3 more
semanticscholar   +1 more source

Flunarizine in Prophylaxis of Childhood Migraine: A Double-Blind, Placebo-Controlled, Crossover Study

Cephalalgia, 1988
An 8-month, double-blind, placebo-controlled, crossover trial of flunarizine in the prophylaxis of migraine has been performed in 70 children. After 4 weeks of medication-free base-line observation, 35 children (group A) received flunarizine (5 mg/day ...
F. Sorge, R. Simone, E. Marano, M. Nolano, G. Orefice, P. Carrieri   +5 more
semanticscholar   +1 more source

Blindness and the Validity of the Double-Blind Procedure

Journal of Clinical Psychopharmacology, 1985
This article describes a method for assessing whether the blindness of a double-blind study is maintained and, if not, whether failure to maintain blindness could have invalidated the results of the study. The benefit of using the method is illustrated in a study of the effect of nicotine gum on the tobacco withdrawal syndrome.
Dean D. Krahn, John R. Hughes
openaire   +3 more sources

Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma.

Journal of Clinical Oncology, 2019
PURPOSE SARC024 is a phase II clinical trial of the multikinase inhibitor regorafenib in specific sarcoma subtypes, including advanced osteosarcoma. We hypothesized that regorafenib would improve progression-free survival (PFS) in patients with sarcoma ...
L. Davis, V. Bolejack, C. Ryan, K. Ganjoo, E. Loggers, S. Chawla, M. Agulnik, M. Livingston, D. Reed, V. Keedy, D. Rushing, S. Okuno, D. Reinke, R. Riedel, S. Attia, L. Mascarenhas, R. Maki   +16 more
semanticscholar   +1 more source

Blind and Double-Blind Techniques [PDF]

JAMA: The Journal of the American Medical Association, 1969
To the Editor:— This communication is stimulated by Dr. A. Hoffer's letter to The Journal claiming historic priority for the first double— blind study in psychiatry.1 My historic research, not yet completed, indicates that the first double-blind study was done by Rivers (1908) in experimental psychology.2The termdouble-blindwas not used to describe ...
openaire   +1 more source